Anakinra

Generic Name
Anakinra
Brand Names
Kineret
Drug Type
Biotech
Chemical Formula
-
CAS Number
143090-92-0
Unique Ingredient Identifier
9013DUQ28K
Background

Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the managemen...

Indication

Anakinra is an interleukin-1 receptor antagonist indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). Anakinra can be used alone or in combin...

Associated Conditions
Coronavirus Disease 2019 (COVID‑19), Cryopyrin-associated Periodic Syndromes (CAPS), Deficiency of the interleukin-1 receptor antagonist, Idiopathic Recurrent Pericarditis, Moderately to Severely Active Rheumatoid Arthritis, Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA)
Associated Therapies
-
Clinical Trials
Related News

Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis

Phase 2
Completed
Conditions
Cardiac Sarcoidosis
Interventions
Drug: Anakinra
First Posted Date
2019-07-12
Last Posted Date
2024-07-10
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
23
Registration Number
NCT04017936
Locations
🇺🇸

University of Michigan Sarcoidosis Clinic, Ann Arbor, Michigan, United States

🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

Open-label Study of Anakinra in MPS III

Phase 1
Completed
Conditions
Mucopolysaccharidosis III
Interventions
Biological: anakinra
First Posted Date
2019-07-12
Last Posted Date
2024-10-22
Lead Sponsor
Lynda E Polgreen
Target Recruit Count
24
Registration Number
NCT04018755
Locations
🇺🇸

The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, United States

Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

Completed
Conditions
Still Disease, Juvenile Onset
Interventions
Drug: Anakinra
First Posted Date
2019-04-30
Last Posted Date
2019-11-14
Lead Sponsor
Swedish Orphan Biovitrum
Target Recruit Count
306
Registration Number
NCT03932344
Locations
🇮🇹

IRCCS Istituto G. Gaslini, Genova, Italy

A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF

Phase 2
Recruiting
Conditions
Cystic Fibrosis, 10011762
Interventions
Drug: Anakinra
First Posted Date
2019-04-24
Last Posted Date
2023-12-13
Lead Sponsor
Heidelberg University
Target Recruit Count
52
Registration Number
NCT03925194
Locations
🇩🇪

Universitätsmedizin Essen, Ruhrlandklinik, Essen, Nordrhein-Westfalen, Germany

🇩🇪

University Children's Hospital Heidelberg, Cystic Fibrosis Centre, Heidelberg, Baden-Württemberg, Germany

🇩🇪

Charité - Universitätsmedizin Berlin, Berlin, Germany

Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2

First Posted Date
2019-01-08
Last Posted Date
2024-11-06
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
102
Registration Number
NCT03797001
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

First Posted Date
2018-04-27
Last Posted Date
2024-12-17
Lead Sponsor
Duke University
Target Recruit Count
1600
Registration Number
NCT03511118
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States

🇺🇸

Loma Linda University Health, Loma Linda, California, United States

and more 19 locations

Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects

Phase 1
Conditions
Blepharokeratoconjunctivitis
Interventions
Drug: IL-1Ra
First Posted Date
2017-12-26
Last Posted Date
2017-12-26
Lead Sponsor
Beijing Tongren Hospital
Target Recruit Count
34
Registration Number
NCT03383276
Locations
🇨🇳

Beijing TongRen Hospital, Beijing, China

A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis

First Posted Date
2017-11-06
Last Posted Date
2020-07-29
Lead Sponsor
Hellenic Institute for the Study of Sepsis
Target Recruit Count
36
Registration Number
NCT03332225
Locations
🇬🇷

Intensive Care Unit, "G.Gennimatas" Thessaloniki General Hospital, Salónica, Greece

🇬🇷

Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece

🇬🇷

Intensive Care Unit, Center for Accident Rehabilitation (KAT) of Athens, Athens, Kifissia, Greece

and more 10 locations

SC IL-1Ra in SAH - Phase III Trial (SCIL)

Phase 3
Active, not recruiting
Conditions
Subarachnoid Hemorrhage
Interventions
Drug: IL-1Ra Placebo
Drug: IL-1Ra
First Posted Date
2017-08-15
Last Posted Date
2023-11-21
Lead Sponsor
University of Manchester
Target Recruit Count
612
Registration Number
NCT03249207
Locations
🇬🇧

Derriford Hospital, Plymouth, Devon, United Kingdom

🇬🇧

Royal Sussex County Hospital, Brighton, United Kingdom

🇬🇧

University Hospital of Wales, Cardiff, Wales, United Kingdom

and more 14 locations

Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Anakinra
First Posted Date
2017-07-31
Last Posted Date
2024-11-18
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
9
Registration Number
NCT03233776
Locations
🇳🇱

Radboud university medical center, Nijmegen, Netherlands

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy